Thomas Schuetz,

Cambridge, Massachusetts, United States
Thomas J. Schuetz, M.D., Ph.D. has over 20 years of experience in oncology, biopharmaceutical drug development and life science venture investing. He co-founded Compass in 2014 following conceptual discussions while he was a venture partner at OrbiMed. As a physician-scientist and serial entrepreneur, he aspired to create an antibody therapeutic company based on novel biology, protein engineering and key medical insights gathered throughout his career. While at OrbiMed, Thomas co-founded Audentes Therapeutics, now a publicly traded biotechnology company where he remains a director. Also, at OrbiMed, he was responsible for the investments in Enobia Pharma, Relypsa and Arteaus Therapeutics, and served as a director at each of those companies. Enobia was acquired by Alexion Pharmaceuticals in 2011, Relypsa was acquired by Galencia in 2016 and Arteaus was acquired by Eli Lilly in 2014. Thomas has multiple years of clinical strategy, development and operations experience including roles as chief medical officer of Therion Biologics Corporation, a cancer vaccine company, and as the vice president of clinical affairs at Transkaryotic Therapies, a company acquired by Shire.

Thomas completed his medical training at Massachusetts General Hospital, where he served as the chief medical resident, and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Thomas holds a B.S. in chemistry from Xavier University, an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University. Thomas is board certified in medical oncology.
Speaking In
10:00 AM - 10:55 AM
Thursday, June 11
Since the first FDA approved bispecific antibody Blincyto hit the market in 2015, a wave of new…